Amgen stock falls after Kissei warns on Tavneos liver risks

Amgen shares fell 2.1% after regulators intensified scrutiny of Tavneos, with Japan reporting 20 fatal cases, including 13 tied to Vanishing Bile Duct Syndrome, and the FDA proposing to withdraw U.S. approval. The FDA had already warned on March 31, 2026 about severe drug-induced liver injury, while the EMA opened a review on January 30, 2026 over Phase III data integrity concerns. Tavneos generated 11.524 billion yen of revenue in Kissei's fiscal year ended March 2026, but the drug's growth outlook is now under significant regulatory and safety pressure.

Analysis

AMGN is facing a classic late-cycle franchise risk: the market is no longer pricing a one-off safety scare, but the possibility that the asset becomes effectively non-bankable across major regions. The second-order issue is not just lost Tavneos revenue; it is whether regulators and payers start extrapolating this signal to other high-risk immunology launches, forcing a higher discount rate on the company’s pipeline and a lower multiple on the acquired Horizon portfolio.

Near term, the overhang is asymmetric because the next catalysts are all negative-skew: label restrictions, suspension of new starts, reimbursement reviews, and potential litigation. If the FDA/EMA rhetoric hardens over the next 2-6 weeks, the market will likely re-rate AMGN on a “stewardship failure” basis rather than a simple product-specific event, which tends to compress multiple before analysts meaningfully cut numbers.

The contrarian angle is that the market may ultimately view this as contained to a relatively niche asset, with limited cash flow durability once new starts are curtailed. If that happens, the equity could stabilize faster than the headline flow suggests; however, that is a months-long thesis and requires no incremental regulatory escalation. The key tell is whether regulators move from warnings to coordinated withdrawal language, which would flip this from a manageable drag into a broader governance and M&A credibility problem.

Key Decisions for Investors

• Short AMGN into regulatory follow-through risk over the next 2-4 weeks; use any bounce on headline fatigue to build. Risk/reward favors a 1.5-2.0x downside capture if the FDA/EMA process moves from review to formal action.
• Buy AMGN put spreads 1-3 months out rather than outright puts; structure for a controlled event-driven move with limited theta bleed if the stock chops on uncertainty.
• Pair trade: short AMGN vs long a diversified large-cap biotech basket or a lower-regulation cash compounder in healthcare. The thesis is multiple compression in AMGN from company-specific governance/regulatory risk, not sector beta.
• Trim exposure ahead of any near-term FDA/EMA decision point; if no escalation emerges within 6-8 weeks, cover part of the short because the trade becomes more about legal overhang than incremental fundamental deterioration.
• Avoid bottom-fishing until there is evidence of stabilized prescribing behavior and no further regulator coordination; the risk/reward is still skewed toward lower estimates before it becomes a valuation story.